<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Res Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Res Med Sci</journal-id><journal-id journal-id-type="publisher-id">JRMS</journal-id><journal-title-group><journal-title>Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1735-1995</issn><issn pub-type="epub">1735-7136</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25709650</article-id><article-id pub-id-type="pmc">4333517</article-id><article-id pub-id-type="publisher-id">JRMS-19-1118</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Pimpinella anisum in modifying the quality of life in patients with functional dyspepsia: A double-blind randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ghoshegir</surname><given-names>S. Ashraffodin</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Mazaheri</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="aff2">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Ghannadi</surname><given-names>Alireza</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Feizi</surname><given-names>Awat</given-names></name><xref ref-type="aff" rid="aff4">3</xref></contrib><contrib contrib-type="author"><name><surname>Babaeian</surname><given-names>Mahmoud</given-names></name><xref ref-type="aff" rid="aff5">4</xref></contrib><contrib contrib-type="author"><name><surname>Tanhaee</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Karimi</surname><given-names>Mehrdad</given-names></name><xref ref-type="aff" rid="aff6">5</xref></contrib><contrib contrib-type="author"><name><surname>Adibi</surname><given-names>Peyman</given-names></name><xref ref-type="aff" rid="aff7">6</xref></contrib></contrib-group><aff id="aff1">Department of Iranian Traditional Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran</aff><aff id="aff2"><label>1</label>Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff3"><label>2</label>Department of Pharmacognosy, School of Pharmacy and Pharmaceutical Sciences, Isfahan, Iran</aff><aff id="aff4"><label>3</label>Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff5"><label>4</label>Department of Iranian Traditional Medicine, Faculty of Medicine, Shahed University, Tehran, Iran</aff><aff id="aff6"><label>5</label>Iranian Traditional Medicine School, Tehran University of Medical Science, Tehran, Iran</aff><aff id="aff7"><label>6</label>Integrative FunctionalGastroenterology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Mohammad Mazaheri, Department of Iranian Traditional Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. E-mail: <email xlink:href="mazaherimohammad@yahoo.com">mazaherimohammad@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2014</year></pub-date><volume>19</volume><issue>12</issue><fpage>1118</fpage><lpage>1123</lpage><history><date date-type="received"><day>12</day><month>6</month><year>2014</year></date><date date-type="rev-recd"><day>16</day><month>7</month><year>2014</year></date><date date-type="accepted"><day>18</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Journal of Research in Medical Sciences</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>We aimed to assess the effects of anise on quality of life (QOL) of patients with functional dyspepsia (FD) in a double-blind randomized clinical trial.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>Of 180 patients attending the gastroenterology clinic, 107 ones with the diagnosis of postprandial distress syndrome according to Rome III criteria were enrolled. They were randomized into two groups, anise and placebo. Anise group involved 47 patients and received anise powders, 3 g after each meal (3 times/day) for 4 weeks. Control group had 60 patients who received placebo powders (cornstarch), 3 g after each meal (3 times/day) for 4 weeks. The QOL was assessed by short-form (SF)-36 questionnaire. Mean scores of eight health domains of the two groups were compared at baseline and at the end of study.</p></sec><sec id="st3"><title>Results:</title><p>The age, sex, body mass index, smoking history, tea and coffee drinking patterns of the two groups were not significantly different. All domains of SF-36 were similar between the two groups at baseline but were significantly different at week 12. At baseline, mean score of physical component summary was 159 in placebo group and 167 in anise group (<italic>P</italic> = 0.1). At week 12, the score was 141 in placebo group and 251 in anise group (<italic>P</italic> = 0.0001). Mean baseline score of mental component summary was 172 and 165 in placebo and anise groups, respectively (<italic>P</italic> = 0.1). At week 12, the score was 135 in placebo group and 233 in anise group (<italic>P</italic> = 0.0001).</p></sec><sec id="st4"><title>Conclusion:</title><p>The current study revealed the effectiveness of anise in improvement of QOL in patients with FD.</p></sec></abstract><kwd-group><kwd>Anise</kwd><kwd>functional dyspepsia</kwd><kwd><italic>Pimpinella anisum</italic></kwd><kwd>postprandial distress syndrome</kwd><kwd>quality of life</kwd><kwd>short-form-36</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Functional dyspepsia (FD) is the most frequent gastrointestinal (GI) disorder. It is diagnosed by upper GI symptoms of bothersome early satiety, postprandial fullness, and epigastric pain/burning for &#x02265;12 weeks began within the last 6 months with no evidence of structural pathologies.[<xref rid="ref1" ref-type="bibr">1</xref>] The prevalence of FD in most populations has roughly been around 10-40%.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref>] Its prevalence in Iran has been about 3-30%.[<xref rid="ref5" ref-type="bibr">5</xref>] The etiology of FD is multifactorial.[<xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref>] Rome III criteria considered two main subtypes for FD: Epigastric pain syndrome and postprandial distress syndrome (PDS). PDS includes patients with meal-related symptoms of bothersome early satiety and postprandial fullness.[<xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref>] The quality of life (QOL) in most patients is impaired[<xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref17" ref-type="bibr">17</xref><xref rid="ref18" ref-type="bibr">18</xref><xref rid="ref19" ref-type="bibr">19</xref>] which induces low work productivity,[<xref rid="ref20" ref-type="bibr">20</xref><xref rid="ref21" ref-type="bibr">21</xref>] high economic costs on society,[<xref rid="ref22" ref-type="bibr">22</xref>] higher anxiety[<xref rid="ref23" ref-type="bibr">23</xref><xref rid="ref24" ref-type="bibr">24</xref><xref rid="ref25" ref-type="bibr">25</xref><xref rid="ref26" ref-type="bibr">26</xref>] and irregular health care seeking behavior.[<xref rid="ref27" ref-type="bibr">27</xref><xref rid="ref28" ref-type="bibr">28</xref><xref rid="ref29" ref-type="bibr">29</xref>] There were some observations that dysmotility-like symptoms more than other symptoms negatively affected the daily activities and QOL of patients with FD.[<xref rid="ref30" ref-type="bibr">30</xref><xref rid="ref31" ref-type="bibr">31</xref><xref rid="ref32" ref-type="bibr">32</xref>] The usual treatment of FD gained limited satisfaction among the patients.[<xref rid="ref33" ref-type="bibr">33</xref>] This led to seeking alternative approaches such as herbal medicines. One of the latter gained popularity in ancient Persian medicine was <italic>Pimpinella anisum</italic> (anise). It showed various therapeutic characteristics in GI system such as inhibition of mucosal damage in stomach, relieving constipation and alleviating nausea.[<xref rid="ref34" ref-type="bibr">34</xref><xref rid="ref35" ref-type="bibr">35</xref><xref rid="ref36" ref-type="bibr">36</xref>] There is no published study on the effects of anise on QOL in patients with FD. We used the most commonly used generic questionnaire in GI disorders, 36-item short-form (SF-36) general health (GH) survey,[<xref rid="ref31" ref-type="bibr">31</xref>] to compare the effects of anise fruit on physical and mental health (MH) status in these patients.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><sec id="sec2-1"><title>Study design</title><p>This was a double-blind randomized clinical trial carried out at GI Clinic of University Hospital (Alzahra) affiliated with the Isfahan University of Medical Sciences (IUMS). The study was registered in Iranian Registry of Clinical Trials (IRCT registration number, 2013101214980). Ethical Committee at IUMS approved the study protocol. A written consent was obtained from all patients. A total of 180 patients were evaluated from August 2013 to March 2014. Those aged 18-65 years and were diagnosed with PDS according to Rome III criteria were enrolled.</p><p>The patients experienced discomfort feeling of postprandial fullness and/or early satiety several times per week in the last 6 months. The following conditions were considered as exclusion criteria: Pregnancy, breastfeeding, peptic ulcer, gastroesophageal reflux disease, dysphagia, celiac, GI surgery, irritable bowel syndrome, abdominal pain, night diarrhea, greasy or black stool, blood in stool, mental retardation, immune system disorders, major depression, bipolar disorder and psychosomatic disorders, severe recent weight loss, cancer, renal disorders, current use of antibiotics, proton pump inhibitors, H2 blockers, bismuth, metoclopramide, domperidone, lactulose, nonsteroid antiinflammatory drugs, corticosteroids, herbal medicines and drug abuse. Patients who took &#x0003c;80% of administered medication or had drug intolerance were withdrawn from the study.</p></sec><sec id="sec2-2"><title>Subjects and intervention</title><p>Seventy-three patients were excluded from the study and 107 patients were enrolled in the study [<xref ref-type="fig" rid="F1">Figure 1</xref>]. They were randomized by simple randomization method into intervention and placebo groups. Intervention group involved 47 patients who received anise powder, 3 g after each meal (3 times/day). According to the Barnes <italic>et al</italic>.,[<xref rid="ref37" ref-type="bibr">37</xref>] administration of up to 20 g/day anise powder is safe. The anise seeds were prepared by Barij Essence Pharmaceutical Company (Mashhad Ardehal, Iran) as a gift. This plant specimen was kept in their herbarium with number 1697.[<xref rid="ref38" ref-type="bibr">38</xref>] Control group involved 60 patients who received placebo powder, 3 g after each meal (3 times/day). Placebo powders consisted of corn starch. They were packed similar to anise powder in shape, color and size. Both powders were prepared in similar packages by Pharmacognosy Department of Isfahan School of Pharmacy at IUMS. The patients were supplied with the medications for 1-week at the beginning of the each week for 4 weeks. Doctors and patients were blind to the assigned treatments.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Consort flowchart of the study</p></caption><graphic xlink:href="JRMS-19-1118-g001"/></fig></sec><sec id="sec2-3"><title>Instruments and outcomes</title><p>The presence of FD was assessed by modified Rome III questionnaire.[<xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref>] FD was diagnosed according to the questionnaire filled-out individually. The QOL was evaluated by Persian version of SF-36 questionnaire. Its reliability and validity has been verified before.[<xref rid="ref39" ref-type="bibr">39</xref>] SF-36 which has been employed successfully in both longitudinal and cross-sectional studies, has 36 items measuring the following eight health domains: Vitality (VT), GH, MH, physical functioning (PF), social functioning (SF), physical role (PR), emotional role (ER), and bodily pain (BP). The scores on each domain may range from 0 to 100, with the higher score indicating better QOL. They reliably assess two major clusters of health: Physical component summary (PCS) and mental component summary (MCS). BP, PF and PR assess the former, whereas MH, ER, and SF assess the latter. GH, SF and VT highly correlate with both PCS and MCS. PCS has showed the highest changes toward interventions targeted physical therapies. MCS has showed the highest changes toward interventions targeted mental therapies. The lowest score of PCS belongs to subjects with frequent feeling of fatigue, severe body pain and limitations in social, physical, role activities and self-care. The highest PCS score belongs to subjects with wellbeing, high levels of energy, no disability and no physical limitations. The lowest MCS score fits in subjects with frequent psychological distress and emotional problems causing social and role disabilities. The highest PCS score fits in subjects with frequent positive affects and no psychological distress and emotional problems causing social and role limitations.[<xref rid="ref40" ref-type="bibr">40</xref>] Follow-up period was 12 weeks. Patients were evaluated at baseline and at the end of week 12. The primary end points were the eight health domains of QOL.</p></sec><sec id="sec2-4"><title>Statistical analysis</title><p>The mean scores of eight domains of SF-36 questionnaire were assessed within each group and between the two groups. Mann-Whitney U-test and Kruskal-Wallis tests were used to compare nonparametric characteristics, and Student's <italic>t</italic>-test was employed to compare parametric characteristics. Intention to treat analysis was applied to analyze the data. <italic>P</italic> &#x0003c; 0.05 was considered as significant. Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA) version 17 for Windows was used to conduct statistical analysis.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>Seventy-three and 107 patients were excluded from and included in the study, respectively. Demographic characteristics of patients in the two groups are compared in <xref ref-type="table" rid="T1">Table 1</xref>. No significant difference was seen in demographic characteristics between the two groups. The mean (standard deviation [SD]) age of patients in the control and intervention group was 41 (11.7) and 45.5 (15.5) years, respectively (<italic>P</italic> = 0.1). The mean (SD) number of drinking tea in control group was 4.76 (2) cups in control group and 4.8 (2.1) cups in anise group. The difference was not significant (<italic>P</italic> = 0.9).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Demographic characteristics of the two groups</p></caption><graphic xlink:href="JRMS-19-1118-g002"/></table-wrap><p><xref ref-type="table" rid="T2">Table 2</xref> shows the range and mean (SD) scores of different domains of SF-36 compared within each group and between the two groups. None of the evaluated eight domains of health showed a significant difference between the two groups at baseline whereas all demonstrated a significant difference at week 12. Furthermore, all eight health domains improved significantly within anise group, whereas all worsened significantly within the placebo group but BP [<xref ref-type="table" rid="T2">Table 2</xref>].</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Different domains of SF36 compared within each group and between the two groups</p></caption><graphic xlink:href="JRMS-19-1118-g003"/></table-wrap><p>Mean baseline PCS score was around 159 and 167 in placebo and anise groups, respectively (<italic>P</italic> = 0.1). At week 12, the score was 141 in placebo group and 251 in anise group which was significantly different (<italic>P</italic> = 0.0001). Mean baseline MCS was about 172 and 165 in placebo and anise groups, respectively (<italic>P</italic> = 0.1). At week 12, the score was 135 in placebo group and 233 in anise group, which was significantly different (<italic>P</italic> = 0.0001). Overall, in anise group PCS score improved more than MCS score whereas in placebo group MCS score worsened more than PCS score by week 12.</p></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>The current study demonstrated that anise may improve the QOL in patients with FD. The most important components of aniseeds essential oils responsible for the observed effects might betrans-anethole, estragole, &#x003b3;-hymachalen, p-anisaldehyde, and methyl chavicol.[<xref rid="ref41" ref-type="bibr">41</xref>] The improvement was observed in all health domains of intervention group and in none of the health domains of placebo group. More than five points increase in score of any domain of SF-36 has been translated as clinically relevant.[<xref rid="ref42" ref-type="bibr">42</xref><xref rid="ref43" ref-type="bibr">43</xref>] The score of all eight health domains improved &#x0003e;5 points in anise group as follows in decreasing order: BP, 53 points, health transition (HT), 42 points, GH, 34 points, SF, 28 points, MH, 24 points, VT, 23 points, PR, 20 points, ER, 15 points and PF, 10 points. The scores of all domains, but BP, in placebo group decreased &#x0003e;5 points by week 12. One item of 36 items of SF-36 is not used in scoring the eight health domains. That is self-evaluated HT item which estimates the changes in overall health status compared to the status of a year ago. &#x0201c;Somewhat better&#x0201d; means an average improvement in HT score of 5.8 points whereas &#x0201c;much better&#x0201d; equals an average score improvement of 13.2.[<xref rid="ref40" ref-type="bibr">40</xref>] More than 42 points increase in HT score in anise group was probably equal to very much better health status compared with that a year ago. On the other hand, &#x0201c;much worse&#x0201d; means an average decline in HT score of 34.4 and &#x0201c;somewhat worse&#x0201d; equals an average score decline of 10.8 points.[<xref rid="ref40" ref-type="bibr">40</xref>] The HT score in placebo group declined &#x0003e;15 points which suggested somewhat worse condition of health status of these patients. Although the improvements of QOL in patients with FD by some therapeutic approaches of modern medicine have been shown in some clinical trials,[<xref rid="ref44" ref-type="bibr">44</xref><xref rid="ref45" ref-type="bibr">45</xref><xref rid="ref46" ref-type="bibr">46</xref><xref rid="ref47" ref-type="bibr">47</xref><xref rid="ref48" ref-type="bibr">48</xref>] there are few studies showing the effects of herbal medicine on QOL in these patients.[<xref rid="ref49" ref-type="bibr">49</xref>]</p><p>The current investigation was the first randomized clinical trial evaluating the effects of anise on QOL of patients with FD. We employed SF-36 SF GH survey to assess the QOL. SF-36 is used universally to evaluate the impact of FD on all aspects of QOL. This is a generic questionnaire to assess patient oriented outcomes of QOL in relation to treatment. It is especially important when comparisons between the two groups are carried out.[<xref rid="ref50" ref-type="bibr">50</xref>] One of the limitations of the study was its single center-based design. This ended to assessment of a homogenous study population and consequently, limited external validity of the findings. Furthermore, the sample size could be larger and the follow-up period could be longer. We suggest including larger sample size with longer periods of follow-up in multiple centers in the future studies. In conclusion, anise was effective in improvement of QOL in patients with FD.</p></sec><sec id="sec1-5"><title>AUTHOR'S CONTRIBUTION</title><p>SAG contributed in the conception of the work, revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. MM contributed in the conception and design of the work, conducting the study, drafting and revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. AG contributed in the design of the work, revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. AF contributed in data analysis, revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. MB contributed in revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. MT contributed in conducting the study, revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. MK contributed in conducting the study, revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. AS contributed in drafting and revising the draft, data analysis, approval of the final version of the manuscript, and agreed for all aspects of the work. PA contributed in the design of the work, revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work.</p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>The authors would like to express their gratitude to Dr. Maryam Mohammadi Masoodi who assisted us in execution of the study. The study was registered in Iranian Registry of Clinical Trials (IRCT registration number, 2013101214980).</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tack</surname><given-names>J</given-names></name><name><surname>Masaoka</surname><given-names>T</given-names></name><name><surname>Janssen</surname><given-names>P</given-names></name></person-group><article-title>Functional dyspepsia</article-title><source>Curr Opin Gastroenterol</source><year>2011</year><volume>27</volume><fpage>549</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">21934617</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vege</surname><given-names>SS</given-names></name><name><surname>Locke</surname><given-names>GR</given-names><suffix>3rd</suffix></name><name><surname>Weaver</surname><given-names>AL</given-names></name><name><surname>Farmer</surname><given-names>SA</given-names></name><name><surname>Melton</surname><given-names>LJ</given-names><suffix>3rd</suffix></name><name><surname>Talley</surname><given-names>NJ</given-names></name></person-group><article-title>Functional gastrointestinal disorders among people with sleep disturbances: A population-based study</article-title><source>Mayo Clin Proc</source><year>2004</year><volume>79</volume><fpage>1501</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15595333</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>H</given-names></name></person-group><article-title>Functional gastrointestinal disorders and overlap syndrome in Korea</article-title><source>J Gastroenterol Hepatol</source><year>2011</year><volume>26</volume><issue>Suppl 3</issue><fpage>12</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">21443700</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Nie</surname><given-names>Y</given-names></name><name><surname>Sha</surname><given-names>W</given-names></name><name><surname>Su</surname><given-names>H</given-names></name></person-group><article-title>The link between psychosocial factors and functional dyspepsia: An epidemiological study</article-title><source>Chin Med J (Engl)</source><year>2002</year><volume>115</volume><fpage>1082</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12173597</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amini</surname><given-names>E</given-names></name><name><surname>Keshteli</surname><given-names>AH</given-names></name><name><surname>Jazi</surname><given-names>MS</given-names></name><name><surname>Jahangiri</surname><given-names>P</given-names></name><name><surname>Adibi</surname><given-names>P</given-names></name></person-group><article-title>Dyspepsia in Iran: SEPAHAN Systematic Review No 3</article-title><source>Int J Prev Med</source><year>2012</year><volume>3</volume><fpage>S18</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">22826763</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>B</given-names></name><name><surname>Liebregts</surname><given-names>T</given-names></name><name><surname>Holtmann</surname><given-names>G</given-names></name></person-group><article-title>Mechanisms of disease: Genetics of functional gastrointestinal disorders &#x02013; searching the genes that matter</article-title><source>Nat Clin Pract Gastroenterol Hepatol</source><year>2007</year><volume>4</volume><fpage>102</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">17268545</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bektas</surname><given-names>M</given-names></name><name><surname>Soykan</surname><given-names>I</given-names></name><name><surname>Altan</surname><given-names>M</given-names></name><name><surname>Alkan</surname><given-names>M</given-names></name><name><surname>Ozden</surname><given-names>A</given-names></name></person-group><article-title>The effect of Helicobacter pylori eradication on dyspeptic symptoms, acid reflux and quality of life in patients with functional dyspepsia</article-title><source>Eur J Intern Med</source><year>2009</year><volume>20</volume><fpage>419</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">19524187</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camilleri</surname><given-names>M</given-names></name><name><surname>Carlson</surname><given-names>P</given-names></name><name><surname>Zinsmeister</surname><given-names>AR</given-names></name><name><surname>McKinzie</surname><given-names>S</given-names></name><name><surname>Busciglio</surname><given-names>I</given-names></name><name><surname>Burton</surname><given-names>D</given-names></name><etal/></person-group><article-title>Neuropeptide S receptor induces neuropeptide expression and associates with intermediate phenotypes of functional gastrointestinal disorders</article-title><source>Gastroenterology</source><year>2010</year><volume>138</volume><fpage>98</fpage><lpage>107.e4</lpage><pub-id pub-id-type="pmid">19732772</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>MK</given-names></name><name><surname>Liu</surname><given-names>SZ</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Immunoinflammation and functional gastrointestinal disorders</article-title><source>Saudi J Gastroenterol</source><year>2012</year><volume>18</volume><fpage>225</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22824763</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farr&#x000e9;</surname><given-names>R</given-names></name><name><surname>Tack</surname><given-names>J</given-names></name></person-group><article-title>Food and symptom generation in functional gastrointestinal disorders: Physiological aspects</article-title><source>Am J Gastroenterol</source><year>2013</year><volume>108</volume><fpage>698</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">23458851</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koloski</surname><given-names>NA</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name></person-group><article-title>Investigating the directionality of the brain&#x02013;gut mechanism in functional gastrointestinal disorders</article-title><source>Gut</source><year>2012</year><volume>61</volume><fpage>1776</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">23293789</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Dumitrascu</surname><given-names>DL</given-names></name></person-group><article-title>Rome III: New standard for functional gastrointestinal disorders</article-title><source>J Gastrointestin Liver Dis</source><year>2006</year><volume>15</volume><fpage>237</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">17013448</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Corazziari</surname><given-names>E</given-names></name><name><surname>Delvaux</surname><given-names>M</given-names></name><name><surname>Spiller</surname><given-names>R</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Thompson</surname><given-names>WG</given-names></name></person-group><article-title>Appendix B: Rome III diagnostic criteria for functional gastrointestinal disorders</article-title><source>Rev Gastroenterol Mex</source><year>2010</year><volume>75</volume><fpage>511</fpage><lpage>6</lpage></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><article-title>Rome Foundation. Guidelines &#x02013; Rome III diagnostic criteria for functional gastrointestinal disorders</article-title><source>J Gastrointestin Liver Dis</source><year>2006</year><volume>15</volume><fpage>307</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">17203570</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filipovic</surname><given-names>BF</given-names></name><name><surname>Randjelovic</surname><given-names>T</given-names></name><name><surname>Ille</surname><given-names>T</given-names></name><name><surname>Markovic</surname><given-names>O</given-names></name><name><surname>Milovanovic</surname><given-names>B</given-names></name><name><surname>Kovacevic</surname><given-names>N</given-names></name><etal/></person-group><article-title>Anxiety, personality traits and quality of life in functional dyspepsia-suffering patients</article-title><source>Eur J Intern Med</source><year>2013</year><volume>24</volume><fpage>83</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">22857883</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aro</surname><given-names>P</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Agr&#x000e9;us</surname><given-names>L</given-names></name><name><surname>Johansson</surname><given-names>SE</given-names></name><name><surname>Bolling-Sternevald</surname><given-names>E</given-names></name><name><surname>Storskrubb</surname><given-names>T</given-names></name><etal/></person-group><article-title>Functional dyspepsia impairs quality of life in the adult population</article-title><source>Aliment Pharmacol Ther</source><year>2011</year><volume>33</volume><fpage>1215</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">21443537</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Oudenhove</surname><given-names>L</given-names></name><name><surname>Vandenberghe</surname><given-names>J</given-names></name><name><surname>Vos</surname><given-names>R</given-names></name><name><surname>Holvoet</surname><given-names>L</given-names></name><name><surname>Demyttenaere</surname><given-names>K</given-names></name><name><surname>Tack</surname><given-names>J</given-names></name></person-group><article-title>Risk factors for impaired health-related quality of life in functional dyspepsia</article-title><source>Aliment Pharmacol Ther</source><year>2011</year><volume>33</volume><fpage>261</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">21083672</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haag</surname><given-names>S</given-names></name><name><surname>Senf</surname><given-names>W</given-names></name><name><surname>H&#x000e4;user</surname><given-names>W</given-names></name><name><surname>Tagay</surname><given-names>S</given-names></name><name><surname>Grandt</surname><given-names>D</given-names></name><name><surname>Heuft</surname><given-names>G</given-names></name><etal/></person-group><article-title>Impairment of health-related quality of life in functional dyspepsia and chronic liver disease: The influence of depression and anxiety</article-title><source>Aliment Pharmacol Ther</source><year>2008</year><volume>27</volume><fpage>561</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">18208571</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Locke</surname><given-names>GR</given-names><suffix>3rd</suffix></name><name><surname>Lahr</surname><given-names>BD</given-names></name><name><surname>Zinsmeister</surname><given-names>AR</given-names></name><name><surname>Tougas</surname><given-names>G</given-names></name><name><surname>Ligozio</surname><given-names>G</given-names></name><etal/></person-group><article-title>Functional dyspepsia, delayed gastric emptying, and impaired quality of life</article-title><source>Gut</source><year>2006</year><volume>55</volume><fpage>933</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16322108</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agr&#x000e9;us</surname><given-names>L</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name></person-group><article-title>Working conditions and family situation in relation to functional gastrointestinal disorders</article-title><source>Scand J Prim Health Care</source><year>1998</year><volume>16</volume><fpage>64</fpage><pub-id pub-id-type="pmid">9612883</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westerberg</surname><given-names>L</given-names></name><name><surname>Theorell</surname><given-names>T</given-names></name></person-group><article-title>Working conditions and family situation in relation to functional gastrointestinal disorders. The Swedish dyspepsia project</article-title><source>Scand J Prim Health Care</source><year>1997</year><volume>15</volume><fpage>76</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">9232707</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fullerton</surname><given-names>S</given-names></name></person-group><article-title>Functional digestive disorders (FDD) in the year 2000 - economic impact</article-title><source>Eur J Surg Suppl</source><year>1998</year><fpage>62</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">10029367</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De la Roca-Chiapas</surname><given-names>JM</given-names></name><name><surname>Sol&#x000ed;s-Ortiz</surname><given-names>S</given-names></name><name><surname>Fajardo-Araujo</surname><given-names>M</given-names></name><name><surname>Sosa</surname><given-names>M</given-names></name><name><surname>C&#x000f3;rdova-Fraga</surname><given-names>T</given-names></name><name><surname>Rosa-Zarate</surname><given-names>A</given-names></name></person-group><article-title>Stress profile, coping style, anxiety, depression, and gastric emptying as predictors of functional dyspepsia: A case-control study</article-title><source>J Psychosom Res</source><year>2010</year><volume>68</volume><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">20004303</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Oudenhove</surname><given-names>L</given-names></name><name><surname>Vandenberghe</surname><given-names>J</given-names></name><name><surname>Dupont</surname><given-names>P</given-names></name><name><surname>Geeraerts</surname><given-names>B</given-names></name><name><surname>Vos</surname><given-names>R</given-names></name><name><surname>Dirix</surname><given-names>S</given-names></name><etal/></person-group><article-title>Abnormal regional brain activity during rest and (anticipated) gastric distension in functional dyspepsia and the role of anxiety: A H(2)(15)O-PET study</article-title><source>Am J Gastroenterol</source><year>2010</year><volume>105</volume><fpage>913</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">20160711</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aro</surname><given-names>P</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Ronkainen</surname><given-names>J</given-names></name><name><surname>Storskrubb</surname><given-names>T</given-names></name><name><surname>Vieth</surname><given-names>M</given-names></name><name><surname>Johansson</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study</article-title><source>Gastroenterology</source><year>2009</year><volume>137</volume><fpage>94</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">19328797</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Oudenhove</surname><given-names>L</given-names></name><name><surname>Vandenberghe</surname><given-names>J</given-names></name><name><surname>Geeraerts</surname><given-names>B</given-names></name><name><surname>Vos</surname><given-names>R</given-names></name><name><surname>Persoons</surname><given-names>P</given-names></name><name><surname>Demyttenaere</surname><given-names>K</given-names></name><etal/></person-group><article-title>Relationship between anxiety and gastric sensorimotor function in functional dyspepsia</article-title><source>Psychosom Med</source><year>2007</year><volume>69</volume><fpage>455</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">17556644</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nozu</surname><given-names>T</given-names></name><name><surname>Kudaira</surname><given-names>M</given-names></name><name><surname>Kitamori</surname><given-names>S</given-names></name><name><surname>Maezawa</surname><given-names>M</given-names></name><name><surname>Uehara</surname><given-names>A</given-names></name></person-group><article-title>Inadequate health care-seeking behavior of Japanese patients with functional gastrointestinal disorders: A preliminary survey</article-title><source>J Gastroenterol</source><year>2002</year><volume>37</volume><fpage>231</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">11931539</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Hui</surname><given-names>W</given-names></name><name><surname>Lam</surname><given-names>S</given-names></name></person-group><article-title>Perceptual style and behavioral pattern of individuals with functional gastrointestinal disorders</article-title><source>Health Psychol</source><year>2000</year><volume>19</volume><fpage>146</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">10762098</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>C</given-names></name></person-group><article-title>Seeking medical consultation: Perceptual and behavioral characteristics distinguishing consulters and nonconsulters with functional dyspepsia</article-title><source>Psychosom Med</source><year>2000</year><volume>62</volume><fpage>844</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">11139005</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Weaver</surname><given-names>AL</given-names></name><name><surname>Zinsmeister</surname><given-names>AR</given-names></name></person-group><article-title>Impact of functional dyspepsia on quality of life</article-title><source>Dig Dis Sci</source><year>1995</year><volume>40</volume><fpage>584</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7895550</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Serag</surname><given-names>HB</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name></person-group><article-title>Health-related quality of life in functional dyspepsia</article-title><source>Aliment Pharmacol Ther</source><year>2003</year><volume>18</volume><fpage>387</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">12940923</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tominaga</surname><given-names>K</given-names></name><name><surname>Higuchi</surname><given-names>K</given-names></name><name><surname>Iketani</surname><given-names>T</given-names></name><name><surname>Ochi</surname><given-names>M</given-names></name><name><surname>Kadouchi</surname><given-names>K</given-names></name><name><surname>Tanigawa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Comparison of gastrointestinal symptoms and psychological factors of functional dyspepsia to peptic ulcer or panic disorder patients</article-title><source>Inflammopharmacology</source><year>2007</year><volume>15</volume><fpage>84</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17450448</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JC</given-names></name></person-group><article-title>Psychological co-morbidity in functional gastrointestinal disorders: Epidemiology, mechanisms and management</article-title><source>J Neurogastroenterol Motil</source><year>2012</year><volume>18</volume><fpage>13</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">22323984</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picon</surname><given-names>PD</given-names></name><name><surname>Picon</surname><given-names>RV</given-names></name><name><surname>Costa</surname><given-names>AF</given-names></name><name><surname>Sander</surname><given-names>GB</given-names></name><name><surname>Amaral</surname><given-names>KM</given-names></name><name><surname>Aboy</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Randomized clinical trial of a phytotherapic compound containing <italic>Pimpinella anisum, Foeniculum vulgare, Sambucus nigra</italic>, and <italic>Cassia augustifolia</italic> for chronic constipation</article-title><source>BMC Complement Altern Med</source><year>2010</year><volume>10</volume><fpage>17</fpage><pub-id pub-id-type="pmid">20433751</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilligan</surname><given-names>NP</given-names></name></person-group><article-title>The palliation of nausea in hospice and palliative care patients with essential oils of <italic>Pimpinella anisum</italic> (aniseed), <italic>Foeniculum vulgare</italic> var. dulce (sweet fennel), <italic>Anthemis nobilis</italic> (Roman <italic>chamomile</italic>) and <italic>Mentha x piperita</italic> (peppermint)</article-title><source>Int J Aromatherapy</source><year>2005</year><volume>15</volume><fpage>163</fpage><lpage>167</lpage></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Mofleh</surname><given-names>IA</given-names></name><name><surname>Alhaider</surname><given-names>AA</given-names></name><name><surname>Mossa</surname><given-names>JS</given-names></name><name><surname>Al-Soohaibani</surname><given-names>MO</given-names></name><name><surname>Rafatullah</surname><given-names>S</given-names></name></person-group><article-title>Aqueous suspension of anise &#x0201c;<italic>Pimpinella anisum</italic>&#x0201d; protects rats against chemically induced gastric ulcers</article-title><source>World J Gastroenterol</source><year>2007</year><volume>13</volume><fpage>1112</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17373749</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>LA</given-names></name><name><surname>Phillipson</surname><given-names>JD</given-names></name></person-group><article-title>Aniseed. Herbal Medicine: A Guide for Health Care Professionals</article-title><year>2007</year><edition>3rd ed</edition><publisher-loc>IL, USA</publisher-loc><publisher-name>Pharmaceutical Press</publisher-name></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazemi</surname><given-names>M</given-names></name><name><surname>Eshraghi</surname><given-names>A</given-names></name><name><surname>Yegdaneh</surname><given-names>A</given-names></name><name><surname>Ghannadi</surname><given-names>A</given-names></name></person-group><article-title>&#x0201c;Clinical pharmacognosy&#x0201d; &#x02014; A new interesting era of pharmacy in the third millennium</article-title><source>Daru</source><year>2012</year><volume>20</volume><fpage>18</fpage><pub-id pub-id-type="pmid">23351785</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motamed</surname><given-names>N</given-names></name><name><surname>Ayatollahi</surname><given-names>AR</given-names></name><name><surname>Zare</surname><given-names>N</given-names></name><name><surname>Sadeghi-Hassanabadi</surname><given-names>A</given-names></name></person-group><article-title>Validity and reliability of the Persian translation of the SF-36 version 2 questionnaire</article-title><source>East Mediterr Health J</source><year>2005</year><volume>11</volume><fpage>349</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">16602453</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Gandek</surname><given-names>B</given-names></name></person-group><article-title>Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project</article-title><source>J Clin Epidemiol</source><year>1998</year><volume>51</volume><fpage>903</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">9817107</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shojaii</surname><given-names>A</given-names></name><name><surname>Abdollahi</surname><given-names>Fard M</given-names></name></person-group><article-title>Review of Pharmacological Properties and Chemical Constituents of <italic>Pimpinella anisum</italic></article-title><source>ISRN Pharm 2012</source><year>2012</year><comment>510795</comment></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Verlinden</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name></person-group><article-title>Validity of a new quality of life scale for functional dyspepsia: A United States multicenter trial of the Nepean Dyspepsia Index</article-title><source>Am J Gastroenterol</source><year>1999</year><volume>94</volume><fpage>2390</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10483997</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bensoussan</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>SW</given-names></name><name><surname>Menzies</surname><given-names>RG</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name></person-group><article-title>Application of the general health status questionnaire SF36 to patients with gastrointestinal dysfunction: Initial validation and validation as a measure of change</article-title><source>Aust N Z J Public Health</source><year>2001</year><volume>25</volume><fpage>71</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11297307</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>YK</given-names></name><name><surname>Choi</surname><given-names>MG</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>IS</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Chung</surname><given-names>IS</given-names></name><etal/></person-group><article-title>The effect of mosapride on quality of life in functional dyspepsia</article-title><source>Korean J Gastroenterol</source><year>2004</year><volume>43</volume><fpage>160</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15034286</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashash</surname><given-names>JG</given-names></name><name><surname>Abdul-Baki</surname><given-names>H</given-names></name><name><surname>Azar</surname><given-names>C</given-names></name><name><surname>Elhajj</surname><given-names>II</given-names></name><name><surname>El Zahabi</surname><given-names>L</given-names></name><name><surname>Chaar</surname><given-names>HF</given-names></name><etal/></person-group><article-title>Clinical trial: A randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia</article-title><source>Aliment Pharmacol Ther</source><year>2008</year><volume>27</volume><fpage>1148</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">18331614</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaminski</surname><given-names>A</given-names></name><name><surname>Kamper</surname><given-names>A</given-names></name><name><surname>Thaler</surname><given-names>K</given-names></name><name><surname>Chapman</surname><given-names>A</given-names></name><name><surname>Gartlehner</surname><given-names>G</given-names></name></person-group><article-title>Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents</article-title><source>Cochrane Database Syst Rev</source><year>2011</year><comment>CD008013</comment></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mearin</surname><given-names>F</given-names></name><name><surname>Rodrigo</surname><given-names>L</given-names></name><name><surname>P&#x000e9;rez-Mota</surname><given-names>A</given-names></name><name><surname>Balboa</surname><given-names>A</given-names></name><name><surname>Jim&#x000e9;nez</surname><given-names>I</given-names></name><name><surname>Sebasti&#x000e1;n</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: A randomized, double-masked trial</article-title><source>Clin Gastroenterol Hepatol</source><year>2004</year><volume>2</volume><fpage>301</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15067624</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meineche-Schmidt</surname><given-names>V</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Pap</surname><given-names>A</given-names></name><name><surname>Kordecki</surname><given-names>H</given-names></name><name><surname>Schmid</surname><given-names>V</given-names></name><name><surname>Ohlsson</surname><given-names>L</given-names></name><etal/></person-group><article-title>Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study</article-title><source>Scand J Gastroenterol</source><year>1999</year><volume>34</volume><fpage>566</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">10440605</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottillinger</surname><given-names>B</given-names></name><name><surname>Storr</surname><given-names>M</given-names></name><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>Allescher</surname><given-names>HD</given-names></name></person-group><article-title>STW 5 (Iberogast&#x000ae;) &#x02013; a safe and effective standard in the treatment of functional gastrointestinal disorders</article-title><source>Wien Med Wochenschr</source><year>2013</year><volume>163</volume><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">23263639</pub-id></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mon&#x000e9;s</surname><given-names>J</given-names></name><name><surname>Adan</surname><given-names>A</given-names></name><name><surname>Seg&#x000fa;</surname><given-names>JL</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>JS</given-names></name><name><surname>Art&#x000e9;s</surname><given-names>M</given-names></name><name><surname>Guerrero</surname><given-names>T</given-names></name></person-group><article-title>Quality of life in functional dyspepsia</article-title><source>Dig Dis Sci</source><year>2002</year><volume>47</volume><fpage>20</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11837724</pub-id></element-citation></ref></ref-list></back></article>